Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00061373 · ClinicalTrials.gov registry record · Phase 2

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

A Phase 2 study of Ischemic Stroke, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

Completed
Registry status
Phase 2
Development phase
18
Enrollment target
3
Study locations

NCT00061373 is a Phase 2 study of Ischemic Stroke that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 18 participants, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00061373, a Phase 2 study of Ischemic Stroke, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

COMPLETED
Registry status
Phase 2
Development phase
18 participants
Enrollment target
3
Study locations

Study Summary

Ischemic stroke is caused by a blood clot that blocks the flow of blood to the brain and damages brain cells. The clot, or thrombus, is made up of platelets and fibrin. The medicine alteplase, also known as tPA , is the standard drug used to treat patients with acute ischemic stroke. tPA attacks the fibrin portion of the blood clot. While intravenous (iv) tPA alone is effective in treating the fibrin part of the clot approximately 30% of the time, adding other commercially available drugs such eptifibatide to treat other clot components may improve the effectiveness of iv tPA therapy. This is a clinical trial to determine an acceptable dose of eptifibatide in combination with aspirin, the low molecular weight heparin tinzaparin, and standard iv tPA therapy for the treatment of acute ischemic stroke. Use of clinical and imaging based selection criteria are hypothesized to contribute to treatment safety by selecting patients at lower risk of intracerebral hemorrhage. Also,selection and evaluation of patients by magnetic resonance imaging (MRI) criteria will result in a different risk to benefit ratio than selecting patients without MRI criteria and will lead to a different acceptable dose.

Conditions Studied

Ischemic Stroke

Interventions

  • DRUG Aspirin
  • DRUG tinzaparin sodium
  • DRUG eptifibatide

Study Locations (3)

Maryland

  • National Institutes of Health Clinical Center - Bethesda
  • Suburban Hospital - Bethesda

District of Columbia

  • Washington Hospital Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2003-05
Est. Completion 2011-07
Phase Phase 2

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

567 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00061373

The ClinicalTrials.gov registry entry for NCT00061373 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (99% lower). The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 3 interventions - of which Aspirin is the first listed.

NCT00061373 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Maryland, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00061373 about?

NCT00061373 is a clinical study titled "Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)". Ischemic stroke is caused by a blood clot that blocks the flow of blood to the brain and damages brain cells. The clot, or thrombus, is made up of platelets and fibrin. The medicine alteplase, also known as tPA , is the standard drug used to treat patients with acute ischemic stroke. tPA attacks the...

What is the current status of trial NCT00061373?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2003-05. Estimated completion is 2011-07.

What conditions does trial NCT00061373 study?

This clinical trial studies the following conditions: Ischemic Stroke.

What interventions are being tested in trial NCT00061373?

The interventions under investigation include: Aspirin (DRUG), tinzaparin sodium (DRUG), eptifibatide (DRUG).

Who is sponsoring clinical trial NCT00061373?

This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00061373 being conducted?

This trial has 3 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ischemic Stroke

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.